Trinity Biotech plc

NASDAQ:TRIB

Medical - Diagnostics & Research

Healthcare
$5.83 -5.73%

-$0.51 today

Market cap
$117.96M
Beta
1.00
P/E (TTM)
-0.1
EPS (TTM)
-$60.27
52W Low $8.00High $103.20

Volume 0.00M

Average 1.34M

TRIB Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Trinity Biotech plcNASDAQ: TRIB

Net Margin · Q4 FY2025 · quarter ended Dec 2025

Net margin narrows to -157.8%

Net margin was -157.8% in Q4 FY2025, down 50.9 pp from a year earlier. On a trailing-twelve-month basis it was -85.3%, down 33.7 pp year over year. Over 3 fiscal years it narrowed by 19.8 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 1 analysts of -34.0% for the fiscal year ending Dec 2026, up from -85.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-157.8%-122.0 pp QoQ
Last fiscal yearDec 2025
-85.4%-33.7 pp YoY
LTMDec 2025
-85.3%-33.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-50.9 pp+62.1 pp+113.1 pp
1 year-33.7 pp+51.3 pp+85.1 pp
3 years-19.8 pp——
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-85.4%
Year-over-year change
-33.7pp
Reported Analyst consensus estimate

Net Margin vs competitors

How TRIB compares with its peers on the latest reported figures

No competitor Net Margin figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.15M62.52M56.83M61.56M43.79M
Cost of Revenue54.89M52.73M37.38M40.11M26.9M
Gross Profit33.45M22.05M19.45M21.44M16.89M
Gross Margin41.2%35.3%34.2%34.8%38.6%
Research & Development4.5M4.14M4.38M4.54M3.63M
Selling, General & Admin24.68M29.17M31.15M28.82M24.67M
Operating Expenses29.52M32.96M46.5M42.61M28.3M
Depreciation & Amortization2.74M2.33M1.78M1.87M2.68M
EBITDA10.59M(16.71M)(24.1M)(16.91M)(21.38M)
EBITDA Margin13.1%-26.7%-42.4%-27.5%-48.8%
Operating Income3.94M(15.27M)(27.05M)(21.17M)(11.42M)
Operating Margin4.9%-24.4%-47.6%-34.4%-26.1%
Interest Income1.22M303K1.17M0221K
Interest Expense7.1M24.73M10.15M9.57M13.11M
Other Income / Expenses(5.86M)(24.43M)(9.88M)(9.57M)(25.76M)
Income Before Tax(1.92M)(43.78M)(36.93M)(30.73M)(37.18M)
Pre-Tax Margin-2.4%-70.0%-65.0%-49.9%-84.9%
Income Tax Expense(74K)(194K)(59K)486K199K
Net Income875K(41M)(24.02M)(31.79M)(37.38M)
Net Margin1.1%-65.6%-42.3%-51.6%-85.4%
EPS (Basic)6.30(180.00)(96.00)(52.98)(60.00)
EPS (Diluted)4.92(156.00)(96.00)(52.98)(60.00)
Weighted Avg Shares139.34K224.9K255.17K598.65K619.19K
Weighted Avg Shares (Diluted)177.53K259.16K255.17K598.65K619.19K

Trinity Biotech plc

NASDAQ:TRIB

Intrinsic Alpha fair value

Locked

Current Price

$5.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.